This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The interventions were no screening, which was not screening contacts and not offering preventive therapy; test-andtreat, which was testing contacts and treating those with a positive test, and treat-all, which was offering preventive therapy to all contacts in the subgroup without testing. Test-and-treat was compared with no screening and treat-all was compared with test-and-treat. Tuberculin skin test was positive when reaction was 5mm or more. Treatment was the standard, nine-month course of isoniazid.
These three strategies were analysed in different subgroups of individuals, such as household versus non-household contacts, prior history of Bacillus Calmette-Guerin (BCG) vaccination or not, age group (under 10 years versus older), and ethnicity (foreign-born, aboriginal, and Canadian-born non-aboriginal). The optimal strategy was determined for each of these subgroups and compared with the current strategy in the authors' setting (test-and-treat) and with no screening.
Location/setting
Canada/community and primary care.
Methods

Analytical approach:
The analysis was based on a Markov model with a six-year time horizon. The authors stated that a societal perspective was adopted.
Effectiveness data:
The clinical data came from a selection of known, relevant, published sources. Data on occurrence of tuberculosis in contacts (for each subgroup) were obtained from a large population-based provincial registry of tuberculosis contacts in British Columbia. The database covered a 12-year period (1990 to 2001) . A proportional hazards (Cox) regression model was built to estimate the multivariate, adjusted hazard ratio of covariates on the risk of tuberculosis development. Few details on the other sources of data were reported. The key clinical endpoint was the risk of tuberculosis transmission.
